Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases
Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases
SAN DIEGO--(BUSINESS WIRE)--Ryne Biotechnology, Inc. (Ryne Bio), a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological disorders, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4 million Clinical Stage Research Program (CLIN1) grant. This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months.
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
ABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million.
Chicago, IL (February 7, 2023) – Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, has earned the Best of Staffing® Client and Talent Awards by ClearlyRated for the eighth consecutive year and Diamond Award status for the fourth consecutive year.
Body language is a critical aspect of job interviews as it can reveal a great deal about a candidate’s personality, honesty, and genuineness. Knowing what to look out for in terms of body language can help you to make informed decisions about the candidates you’re interviewing, providing further insight into who they really are beyond what they say about themselves.
GSK plc (LSE/NYSE: GSK) today announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in GSK clinical trials. The study looked at clinical trial demographic data from 495 GSK and ViiV clinical trials involving US-based participants from the period 2002 to 2019. The results published today in Clinical Trials: Journal of the Society of Clinical Trials demonstrate that using real world diseases epidemiology data, rather than the traditional benchmark of US Census Bureau race and ethnicity data, would ensure clinical trial enrolment reflects the populations affected by different diseases.
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics
Thermo Fisher’s latest net-zero milestone to be achieved through 200-megawatt solar project
RAVENSBURG, Germany & RANKWEIL, Austria & SKOKIE, Ill.--(BUSINESS WIRE)--With the increasing drug development for novel therapeutics, a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill and finish solutions. And, while the stages of early drug development are challenging, Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting their customer products path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility which has already contributed to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next months.